Prophylactic negative-pressure wound therapy after ileostomy reversal for the prevention of wound healing complications in colorectal cancer patients: a randomized controlled trial - Top-Institutions - MDSpire

Prophylactic negative-pressure wound therapy after ileostomy reversal for the prevention of wound healing complications in colorectal cancer patients: a randomized controlled trial

  • By

  • M. Wierdak

  • M. Pisarska-Adamczyk

  • M. Wysocki

  • P. Major

  • K. Kołodziejska

  • M. Nowakowski

  • T. Vongsurbchart

  • M. Pędziwiatr

  • November 7, 2020

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Colorectal Surgery
    • Wound Care
    • Surgical Oncology

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Colorectal Surgery
    • Oncology
    • Wound Management

  • #3

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Colorectal Surgery
    • Surgical Research
    • Wound Healing

  • #4

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Colorectal Surgery
    • Wound Care
    • Surgical Oncology

  • #5

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Colorectal Surgery
    • Oncology
    • Wound Management

Original Source(s)

Prophylactic negative-pressure wound therapy after ileostomy reversal for the prevention of wound healing complications in colorectal cancer patients: a randomized controlled trial

  • by M. Wierdak, M. Pisarska-Adamczyk, M. Wysocki, P. Major, K. Kołodziejska, M. Nowakowski, T. Vongsurbchart, M. Pędziwiatr

  • November 7, 2020

Related Content

Bridging aging and colorectal cancer: Synergistic roles of inflammaging and immunosenescence

A network analysis of symptom clusters and core symptoms in colorectal cancer patients undergoing postoperative chemotherapy

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min